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Dysregulated fibronectin trafficking 
by Hsp90 inhibition restricts 
prostate cancer cell invasion
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Max Moldovan2, Claire Levrier4, Martin C. Sadowski4, Mei Yieng Chin5, Emma S. Tomlinson 
Guns5, Gerard Tarulli1,6, David J. Lynn2,7, Douglas A. Brooks1,3, Luke A. Selth1,6,  
Margaret M. Centenera1,2 & Lisa M. Butler  1,2
The molecular chaperone Hsp90 is overexpressed in prostate cancer (PCa) and is responsible for the 
folding, stabilization and maturation of multiple oncoproteins, which are implicated in PCa progression. 
Compared to first-in-class Hsp90 inhibitors such as 17-allylamino-demethoxygeldanamycin (17-AAG) 
that were clinically ineffective, second generation inhibitor AUY922 has greater solubility and efficacy. 
Here, transcriptomic and proteomic analyses of patient-derived PCa explants identified cytoskeletal 
organization as highly enriched with AUY922 treatment. Validation in PCa cell lines revealed that 
AUY922 caused marked alterations to cell morphology, and suppressed cell motility and invasion 
compared to vehicle or 17-AAG, concomitant with dysregulation of key extracellular matrix proteins 
such as fibronectin (FN1). Interestingly, while the expression of FN1 was increased by AUY922, FN1 
secretion was significantly decreased. This resulted in cytosolic accumulation of FN1 protein within 
late endosomes, suggesting that AUY922 disrupts vesicular secretory trafficking pathways. Depletion 
of FN1 by siRNA knockdown markedly reduced the invasive capacity of PCa cells, phenocopying 
AUY922. These results highlight a novel mechanism of action for AUY922 beyond its established effects 
on cellular mitosis and survival and, furthermore, identifies extracellular matrix cargo delivery as a 
potential therapeutic target for the treatment of aggressive PCa.
Prostate cancer (PCa) is the second leading cause of cancer-related deaths, and the most commonly diagnosed 
malignancy in Western men1,2. Early diagnosis of localized disease facilitates effective treatment using radiation 
or surgery, but for 20–30% of men these therapies are not curative3. A hallmark of PCa cells is their critical 
dependence on androgen signaling, and the androgen receptor (AR) is the primary therapeutic target for relapsed 
or advanced disease4,5. However, therapy resistance is inevitable, and more recent treatment options such as the 
AR antagonist enzalutamide6 and the CYP17 inhibitor abiraterone acetate7 achieve only limited survival benefits. 
Consequently, there is an urgent need for new therapeutic options to significantly improve survival outcomes.
The molecular chaperone Hsp90 regulates the stabilization, maturation and activation of over 200 client pro-
teins, including the AR8,9. As many Hsp90 clients are known oncoproteins, cancer cells have a greater dependence 
on Hsp90 for growth and survival compared to non-malignant cells10–12. This dependence is further exacerbated 
by the increased number of mutated or misfolded proteins known to accumulate within cancer cells, as these are 
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reliant on Hsp90 to prevent their degradation8,13. Moreover, upregulation of Hsp90 is a common feature of many 
tumor cell types including PCa, making it a potentially selective target for cancer therapy8,13.
Despite promising preclinical efficacy, first-in-class Hsp90 inhibitors such as the geldanamycin derivative 
17-allylamino-demethoxygeldanamycin (17-AAG) have proven to be largely disappointing in clinical trials, 
reviewed in14. Next generation inhibitors, including synthetic small molecules such as AUY922, possess increased 
potency and more favorable pharmacological properties15, suggesting that they may be clinically more efficacious. 
Using patient-derived prostate tumor tissues, cultured as explants, we previously demonstrated that AUY922 has 
greater biological activity than 17-AAG in terms of reducing tumor cell proliferation and inducing apoptosis16. 
An important observation from that study was that both 17-AAG and AUY922 significantly induced the expres-
sion of Hsp70, a clinically-used marker of Hsp90 inhibition, whereas only AUY922 was capable of significantly 
reducing proliferation and inducing apoptosis16,17. The downstream mechanisms that differentiate the relative 
efficacies of next generation versus first-in-class HSP90 inhibitors remain unclear. This study identified pathways 
selectively altered by AUY922, and not 17-AAG, in patient-derived PCa explants and further interrogated the 
influence of those pathways on the anti-tumor activity of AUY922.
Results
Cytoskeletal organization pathways are selectively altered by AUY922 in patient-derived pros-
tate explants. We have previously demonstrated superior efficacy of a second generation (AUY922) versus a 
first generation (17-AAG) Hsp90 inhibitor in PCa cell lines and patient-derived prostate tumor explants, despite 
similar induction of the clinically used biomarker Hsp70. To identify novel gene and protein pathways that may 
underpin this differential anti-proliferative response, patient-derived PCa explants (PDEs) cultured with each 
agent or vehicle alone were analyzed by transcriptomic (RNA-seq, n = 6 patients) and proteomic analyses (n = 12 
patients). As previously reported16, we observed enhanced anti-proliferative effects of AUY922 in both pros-
tate cancer PDE cohorts (Supplementary Figure 1). RNA-seq analysis identified 1698 differentially expressed 
genes (DEGs; p < 0.05) in AUY922 treated PDEs compared with vehicle treatment and 715 DEGs (p < 0.05) 
compared to 17-AAG treated PDEs, see Supplementary Dataset for DE analysis outcomes. At a pathway level, 
the KEGG pathways enriched by AUY922 in the RNA-seq dataset revealed Regulation of Actin Cytoskeleton and 
Extracellular Matrix (ECM) interactions to be the most robustly altered pathways (Fig. 1A). Gene set enrichment 
analysis demonstrates a significant negative association between AUY922 treatment and Regulation of Actin 
Cytoskeleton (Fig. 1A) and ECM interactions (Supplementary Figure 2) pathways and heat maps depict genes 
from both pathways that are exclusively and significantly inhibited by AUY922 (Fig. 1A, Supplementary Figure 2). 
We validated differential regulation of two genes, ANXA2 and AURKB, by qPCR in independent explants 
(Fig. 1A). 2D-DIGE proteomic analysis identified 137 protein spots as differentially expressed in AUY922 treated 
explants compared with vehicle treatment (p < 0.05) and 98 differentially expressed protein spots compared to 
17-AAG (p < 0.05). Proteins of interest were those that were differentially expressed in AUY922 treated PDEs 
compared with both vehicle and 17-AAG, resulting in 26 proteins spots being subjected to identification by 
mass spectrometry. Pathway analysis using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID)18,19 again revealed Regulation of Actin Cytoskeleton as a highly enriched KEGG pathway in AUY922 
treated tumors (Fig. 1B), validating our RNAseq pathway analysis. We validated two proteins, TALDO and ROA1, 
as being selectively regulated by AUY922 in independent explant tissues (Fig. 1B).
The cytoskeleton makes up the structural framework of the cell, thereby governing cell shape and cytoplasmic 
organization while regulating cellular functions such as division and motility. The effect of AUY922 on cytoskel-
etal structure was further reflected in the dramatic morphological changes, including markedly increased cell 
body size (Fig. 2A) that accompanied an overall decrease in cell number, as measured by confluency (Fig. 2B). 
Given the pathways differentially altered by AUY922 compared to 17-AAG in the proteomic and transcriptomic 
analyses, the effects of both drugs on cell motility and invasion through Matrigel were compared in PCa cell lines, 
using equivalent effective doses of each compound with respect to cell viability (IC50). By tracking cell move-
ment over a 48 hour period post-treatment, a significant and rapid decrease in motility of PC-3 and LNCaP cells 
(Fig. 2C) and invasion of PC-3 cells (dose-dependent; Fig. 2D) was observed in the presence of AUY922, but to 
a lesser extent 17-AAG.
Fibronectin is induced in response to AUY922 and accumulates within cytosolic compartments. 
Based on its pronounced effects on cytoskeletal pathways, prostate cell motility and morphology, a panel of 
cytoskeletal and ECM-related proteins was assessed in LNCaP and PC-3 cells cultured for 48 h with IC50 and 
2x IC50 concentrations of AUY922 (25 nM, 50 nM) or 17-AAG (50 nM, 100 nM) (Fig. 3A). Hsp90 inhibition 
was confirmed by expression of the clinical biomarker Hsp70, which was induced in response to both AUY922 
and 17-AAG in LNCaP and PC-3 cells (Fig. 3A). Also in both cell lines, AUY922 did not change expression 
of tubulin or actin relative to vehicle treatment, but decreased the amount of myosin motor protein in a dose 
dependent manner (Fig. 3A). Both agents enhanced the expression of E-cadherin in LNCaP cells but AUY922 
did so to a greater extent; E-Cadherin was not expressed in PC-3 cells. The most notable effect of AUY922 was a 
marked induction of fibronectin (FN1) protein compared to 17-AAG treatment in both cell lines (Fig. 3A). The 
AUY922-selective induction of FN1 observed in PCa cell lines, along with its presence in the ECM and cytoskele-
tal KEGG pathways that were enriched in out transcriptomic data from the PDE tissues (Fig. 1A, Supplementary 
Figure 2), led us to focus on this protein.
Whole cell, cytosolic and nuclear fractions from LNCaP cells indicated that FN1 accumulated within the 
cytosol following 48 h treatment with AUY922 and, to a lesser extent, with 17-AAG (Fig. 3B). Immunofluorescent 
staining showed that although FN1 remained localized to the same cellular compartments in AUY922 treated 
cells compared to vehicle (Fig. 3C), quantitative analysis of the FN1 staining in multiple cells revealed significant 
AUY922-dependent increases in both the number and size of FN1-containing particles (Fig. 3D).
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AUY922 inhibits fibronectin secretion. The function of FN1 is largely considered to rely upon its secre-
tion from the cell and subsequent incorporation into the ECM20,21. However, despite the marked induction of 
FN1 expression in AUY922 treated PCa cells, ELISA assays performed to detect FN1 in the culture medium 
demonstrated that AUY922 (25 nM) caused a consistent and significant reduction in FN1 secretion by LNCaP 
cells compared to vehicle treated cells (Fig. 4A; n = 4 independent experiments).
The cellular secretion of proteins is reliant on endosome traffic along microtubules for delivery to the plasma 
membrane, where the release of ECM proteins including FN1 occurs, allowing for their polymerization and 
deposition in the extracellular space (Fig. 4B). To determine which cytosolic compartments contained FN1, 
co-staining of FN1 was performed in LNCaP cells with a panel of endoplasmic reticulum, Golgi, endosome and 
lysosome vesicle markers including PDI, Tgn46, Appl1, EEA1, Rab5, Rab7, LIMP2 and LAMP1 (Fig. 4C). FN1 
co-located with PDI (endoplasmic reticulum), Tgn46 (Golgi) and, most robustly, vesicles containing the Rab5 
(early endosomal) and Rab7 (late endosomal) markers (Fig. 4C). Visual inspection suggests that colocation of 
FN1 with these markers was unaltered by AUY922 (Supplementary Figure 3).
Suppression of fibronectin secretion is not due to disrupted microtubules or exosome release. To 
further investigate the mechanism of impaired FN1 secretion, the effect of AUY922 on microtubule function was eval-
uated using a tubulin polymerization assay with purified tubulin (Fig. 5A). As expected, the microtubule-destabilizing 
drugs vinblastine and nocodazole inhibited microtubule polymerization, whereas the microtubule-sensitizing drug 
paclitaxel increased microtubule polymerization (Fig. 5A). No direct effect of the Hsp90 inhibitors on tubulin polymer-
ization was detected (Fig. 5A). Moreover, no disruption of the microtubule network was evident in LNCaP cells treated 
with AUY922 (Fig. 5B), nor any changes to the cellular α-tubulin polymer mass (Fig. 5C).
An alternative hypothesis was that AUY922 may affect FN1 secretion via impaired exosome release, as FN1 is 
a reported exosomal cargo protein in PCa cell lines and patient serum22,23. However, there was no consistent effect 
of AUY922 on exosome release in 3 independent cell lines (LNCaP, PC-3 and 22Rv1) (Supplementary Figure 4), 
and the FN1 content of those exosomes was only modestly reduced by AUY922 (Supplementary Figure 5). 
Figure 1. The Hsp90 inhibitor, AUY922, selectively alters cellular pathways involved in the cytoskeleton and ECM. 
(A) KEGG pathways determined by over-representation analysis of differentially expressed genes identified through 
RNA-seq analysis of AUY922 treated PDEs (48 h: 500 nM) using the InnateDB database. A barcode plot and heatmap 
of RNA-seq gene expression data from regulation of actin cytoskeleton pathway for individual explants is shown, 
and significant changes in gene expression were validated in independent explants by qRT-PCR (ANXA2 & AURKB 
shown). (B) KEGG pathways determined by the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) using differentially expressed proteins identified through proteomic analysis of AUY922 treated PDEs 48 h: 
500 nM, n = 12). Proteins identified by 2D-DIGE proteomics analysis were validated in independent PDE samples by 
Western blot. ERK1 was used as loading control. Full-length blots are presented in Supplementary Figure 5.
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Figure 2. Hsp90 inhibition markedly influences cell morphology, growth, motility and invasive capacity. 
(A) Morphology of LNCaP and PC-3 cells cultured +/− AUY922 (25 nM) or 17-AAG (50 nM) for 48 h in the 
Incucyte live cell analysis system. (B) Cell confluency was measured in the same experiment. (C) Motility of 
LNCaP and PC-3 cells cultured +/− AUY922 (25 nM) or 17-AAG (50 nM) over a 48 h incubation in an Incuyte 
live cell analysis system, with 50 cells tracked per treatment. (D) PC-3 cells were cultured with either IC50 or 
2x IC50; AUY922 (25 and 50 nM) or 17-AAG (50 and 100 nM) or vehicle (DMSO) for 48 h before harvesting for 
a 3D invasion assay using 24-well Falcon BioCoat Matrigel invasion chambers. Migrated cells remaining on the 
bottom surface were fixed in formalin and stained with crystal violet. Five random fields for each membrane 
were photographed using the Axio Scope A1 Fluorescent Microscope (Zeiss), and the number of migrated cells 
was counted manually and presented as percent of control cells ± SEM.
www.nature.com/scientificreports/
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Depletion of cellular fibronectin suppresses PCa cell invasion to a similar extent as Hsp90 inhi-
bition. We next investigated whether cellular accumulation or secretion of FN1 was biologically meaningful 
in the efficacy of AUY922 to suppress invasion and migration, or merely a marker of general cytoskeletal and/or 
secretory processes being altered by Hsp90 inhibition. As secretion of FN1 has been implicated as a key mediator 
Figure 3. AUY922 induces expression of fibronectin, resulting in its cytosolic accumulation in punctate 
compartments. (A) Western blot analysis of the effect of 17-AAG or AUY922 on Hsp70, fibronectin (FN1) and 
cytoskeletal proteins, in LNCaP and PC-3 cells. Cells were treated with DMSO control or the indicated doses 
of AUY922, or 17-AAG and collected at 48 h. Full-length blots are presented in Supplementary Figure 6. To 
examine intracellular localization of FN1, we used (B) cellular fractionation of LNCaP cells treated as indicated 
for 48 h (W = whole cell lysate, C = cytoplasmic fraction, N = nuclear fraction; full length blots are presented 
in Supplementary Figure 6), and (C) fluorescence microscopy of LNCaP cells treated for with AUY922 (25 nM) 
for 48 h and probed for FN1 (antibody obtained from Professor Jane Sottile, Rochester University) followed by 
secondary ALEXA 488 with images taken using Leica SP8 confocal microscope at 40x magnification. (D) The 
number and distribution of FN1 particles in cultured LNCaP cells with AUY922 (25 nM) for 48 h was quantified 
by automated image analysis (CellProfiler) of fluorescence microscopy images captured with an INCell 2200 
automated imaging system (GE Healthcare) at 20x magnification.
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of tumor cell invasion and migration, and we found Hsp90 inhibition to suppress FN1 secretion and tumor cell 
invasion (Fig. 2D), a Matrigel invasion assay was employed in PC-3 cells to compare the effects of AUY922 to (a) 
siRNA knockdown of FN1 causing depletion of cellular and secreted FN1, or (b) inhibition of FN1 polymeriza-
tion and ECM fibril deposition using the inhibitory peptide pUR424. Significant, dose-dependent, inhibition of 
Figure 4. Fibronectin is localized to late endosome compartments which require intact tubulin microtubules 
to traffic to the plasma membrane. (A) To examine inhibitor effects on secretion of FN1, an ELISA assay was 
performed on tissue culture media (HPC-1) collected from LNCaP cells treated with AUY922 (25 nM) for 
48 h and controlled for cell number. Date represents mean ± SEM of  4 independent experiments. (B) Model 
illustrating cytosolic vesicle and compartment trafficking to the plasma membrane along microtubule networks. 
(C) Co-location of FN1 with vesicle markers including endosomes (EEA1, Appl1, Rab5, Rab7), lysosome 
(LIMP2, LAMP1), endoplasmic reticulum (PDI) and Golgi (Tgn46) was examined by fluorescence microscopy 
in LNCaP cells treated with DMSO for 48 h and probed for vesicle markers (red) and FN-1 (green) and DAPI 
mount media (blue). Images were taken using Leica SP8 confocal microscope at 63x magnification.
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PC-3 cell invasion was observed using AUY922 (Fig. 6A). Knockdown of FN1 expression by approximately 80% 
was achieved using 2 independent siRNAs, and both caused a significant inhibition of PC-3 cell invasion, to a 
similar degree as AUY922 (Fig. 6B). In contrast, there was no significant effect of the pUR4 inhibitory peptide on 
cell invasion (Fig. 6C), suggesting that fibril deposition of FN1 is not required for invasiveness.
Discussion
The Hsp90 inhibitor AUY922 exhibits potent anti-tumor activity in a variety of cancers, including PCa, which is 
the second leading cause of cancer related deaths for men worldwide25–29. This study aimed to identify the cellular 
and molecular mechanisms that contribute to the enhanced efficacy of this agent compared to the first-in-class 
inhibitor 17-AAG, an outcome that could facilitate development of new and improved therapeutics and/or iden-
tify more appropriate biomarkers of the Hsp90 inhibitor response. Using a transcriptomic approach coupled 
with proteomic analysis of a unique patient-derived explant model, we provide evidence for a novel effect of 
AUY922-mediated inhibition of Hsp90 function leading to altered cytoskeletal organization that is associated 
with changes in fibronectin expression, intracellular delivery and secretion, and is consistent with an impact on 
PCa cell migration and metastatic potential.
Cytoskeletal organization and microtubule dynamics have been associated with tumor cell dissemination and 
metastasis in multiple studies and model systems30–33. Changes in cytoskeletal organization, often driven via 
epithelial to mesenchymal transition (EMT), can mediate increased cancer cell motility, invasion and metasta-
sis30,31,34. Fibronectin is a core glycoprotein component of the extracellular matrix that plays an important role in 
the maintenance and regulation of cell structure, cell adhesion, physiological remodeling, proliferation, differen-
tiation and survival35. Most often in the study of cancer, fibronectin is examined as a marker of the mesenchymal 
phenotype associated with EMT for the purpose of metastasis36, or is considered primarily in the context of 
fibroblastic stroma in the tumor microenvironment. Much less is known about the potential roles that fibronec-
tin may play in normal and malignant epithelium. However, loss of fibronectin expression can contribute to 
reduced adhesion and other morphological changes in tumor cells37. In this study, we discovered that fibronectin 
secretion is markedly reduced in cells treated with AUY922, despite increased expression and accumulation in 
late endosome compartments within the cytosol. Our functional studies demonstrated that siRNA depletion 
of fibronectin expression recapitulated the effects of AUY922 on PCa cell invasion. This led us to speculate that 
reduced fibronectin secretion, rather than the aberrant intracellular accumulation of fibronectin, underlies the 
anti-metastatic effects of AUY922 and is an important area for future investigation.
Figure 5. AUY922 does not affect microtubule polymerization in prostate cancer cells. (A) AUY922, 17-AAG 
and control compounds at the indicated doses were incubated with purified tubulin protein at 37 °C, and 
polymerization was monitored using a FLUOstar Omega plate reader at 340 nm every 1 min for 60 min at 37 °C. 
(B) Representative images of LNCaP cells treated with AUY922 (31 or 250 nM), nocodazole (NOC) (250 nM) or 
vehicle control (DMSO) for 48 h and subjected to fluorescence microscopy of α-tubulin (green) and DNA (blue) 
using an INCell 2200 automated imaging system at 40x magnification. Cells treated with DMSO or AUY922 
showed intact microtubule network, while cells treated with the microtubule destabilizing drug NOC displayed 
depolymerized microtubules. Scale bar = 5 µm. (C) AUY922 (15–500 nM) did not affect α-tubulin polymer 
mass, while NOC (250 nM) and paclitaxel (200 nM) reduced and increased, respectively, α-tubulin polymer 
mass, as shown by quantitative immunofluorescence microscopy of the cellular α-tubulin mean intensity as 
depicted in (B) (expressed as fold-change relative to DMSO control, n = 3, mean ± SD).
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Figure 6. AUY922 and specific knockdown of FN1 both suppress prostate cancer cell invasion. (A) Cells were 
cultured with either AUY922 (25, 50 nM), or vehicle (DMSO) for 48 h before harvesting for the invasion assay. 
(B) PC-3 cells were transfected with 2 independent siRNAs against FN1 (Si-1, Si-2), or non-targeting siRNA 
as a negative control for 48 h before harvesting for the invasion assay. (C) PC-3 cells were treated with pUR4 
(500 nM) or the control peptide III-11C (500 nM) for 48 h before harvesting for the invasion assay. 3D invasion 
assays were conducted in PC-3 cells using 24-well Falcon BioCoat Matrigel invasion chambers. Treated or 
siRNA-transfected cells were seeded into the upper chamber of the Transwell at a density of 1x 105 cells/well 
in serum-free medium. The bottom chamber was filled with RPMI-1640 medium containing 5% FBS and 
inserts incubated at 37 °C for 48 h. Migrated cells remaining on the bottom surface were fixed in formalin and 
stained with crystal violet. Five random fields for each membrane were photographed using the Axio Scope 
A1 Fluorescent Microscope (Zeiss), and the number of migrated cells was counted manually and presented as 
percent of control cells ± SEM.
www.nature.com/scientificreports/
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Although little is currently understood about the mechanistic basis of fibronectin secretion, one previous 
study has suggested that trafficking of fibronectin-containing vesicles occurs via endosome/lysosome pathways 
and that branched microtubule assembly is required for such trafficking to occur38. Our demonstration that 
fibronectin has a punctate pattern of expression within PCa cells, and co-localizes with PDI, Tgn46, Rab5 and 
Rab7, suggests that fibronectin is localized within vesicles in the ER, Golgi, early endosomal and late endoso-
mal compartments. The increase in the number and size of fibronectin-containing particles, toether with the 
enhanced cytoplasmic content of fibronectin, in response to AUY922 treatment likely reflects the accumulation of 
fibronectin-containing vesicles within the cellular cytoplasm. The GTPase Rab7 is localized to the late endosome 
and is involved in directing proteins from the early endosome either via multi-vesicular bodies (MVB) to lyso-
some compartments for degradation or to the cell surface for extracellular release39–41. Co-location of fibronectin 
to these Rab7 endosomes and not the lysosome (LAMP1) suggests that the mechanism of fibronectin trafficking 
and secretion occurs via Rab7 late endosome and MVB exocytosis pathways. Most attention in the literature 
has focused on the integrin-dependent secretion of fibronectin into the extracellular space prior to its polymer-
ization and deposition into a fibrillary matrix. More recently, fibronectin has been detected in association with 
extracellular vesicles released from PCa cell lines and in plasma and urine from clinical patients22,23, suggesting 
an alternative mechanism of cellular release of fibronectin and other matrix-related factors. Importantly, not 
only can extracellular vesicles promote motility and migration of tumor cells42, their cargo of extracellular matrix 
components, and specifically fibronectin located on the outer surface of these vesicles, have been implicated as 
a key mediator of directional invasive capacity, potentially due to stabilization of tumor cell protrusions into the 
stroma and tumor microenvironment43, and/or inter-cellular cross-talk44. While attractive as a mechanism for 
the suppressed fibronectin secretion in AUY922-treated cells, we detected no consistent change in extracellular 
vesicle release from multiple PCa cell lines cultured with AUY922, indicating that the defect likely lies either in 
the integrin-mediated release of MVBs at the plasma membrane or with intracellular trafficking along the micro-
tubule network.
Vesicle trafficking to the plasma membrane is dependent on polymerized microtubule structures and 
microtubule-associated proteins45,46, and several cytoskeletal proteins including actin and tubulin are known 
client proteins of Hsp9047–51. Inhibition of either fibronectin secretion or tubulin microtubule assembly has been 
linked to suppression of adhesion52, apoptosis53–55, metastases56,57 and proliferation54 of tumor cells, and we there-
fore hypothesized that Hsp90 maintains the homeostasis of the microtubule network that provide the framework 
for trafficking of secretory vesicles. Our detailed analysis of both direct and indirect effects of AUY922 on micro-
tubule polymerization and structure revealed no significant effects. We did however observe a marked reduction 
in myosin motor protein expression in response to AUY922, which could indicate that the process of vesicular 
traffic is altered and that this impacts on the delivery of endocytic cargo, thereby reducing secretion of fibronectin 
and promoting its observed accumulation in late endosomes within the enlarged cytosol. Following AUY922 
treatment, the majority of fibronectin was detected in Rab5 and Rab7 endosomes and the size and number of 
fibronectin particles increased in PCa cells, consistent with the intracellular accumulation of fibronectin aggre-
gates in endosomes.
In summary, this study has defined the extracellular matrix component fibronectin as a new cellular target for 
the Hsp90 inhibitor, AUY922, in PCa cells. Importantly, we provide the first evidence that selective suppression 
of fibronectin secretion significantly inhibits the invasive capacity of prostate cancer cells, and AUY922 could 
therefore have potent anti-metastatic action through this pathway. Moreover, as a secreted protein, detection 
of fibronectin in patient serum may be a useful marker of AUY922 activity in vivo. More broadly, we propose 
that defining the cellular responses to cancer therapeutics using a clinically-relevant tumor explant model is a 
powerful new approach to not only glean new insights into drug action, but also identify clinically-relevant bio-
markers that may indicate patient responsiveness and potential new mechanisms of resistance. Here we show that 
molecular chaperone cargo is a new therapeutic target in PCa, where the inhibition of cargo delivery can limit the 
invasive, metastatic potential of aggressive cancer cells.
Materials and Methods
Cell culture and reagents. The human prostate carcinoma cell lines 22Rv1, LNCaP, and PC-3 were 
obtained from the American Type Culture Collection (ATCC). Cell Bank Australia performed verification of all 
cell lines in 2016 via short-tandem repeat profiling. The 22Rv1 and LNCaP cell lines were maintained in RPMI-
1640 medium containing 10% fetal bovine serum (FBS; Sigma Aldrich). The PC-3 cell line was maintained in 
RPMI-1640 medium containing 5% FBS. The Hsp90 inhibitors 17-N-allylamino-17-demethoxygeldanamycin 
(17-AAG; National Cancer Institute) and AUY922 (Novartis, now Vernalis) were dissolved in dimethyl sulfoxide 
(DMSO; Sigma Aldrich). The tubulin modifying drugs paclitaxel and nocodazole (Sigma Aldrich) were dissolved 
in DMSO. The sources and experimental conditions for primary antibodies used in this study are detailed in 
Supplementary Table 1.
Ex Vivo Culture of Human Prostate Tumors. Ethical approval for the use of human prostate tumors 
was obtained from the Ethics Committees of the University of Adelaide (Adelaide, Australia), and St Andrew’s 
Hospital (Adelaide, Australia). All experiments were performed in accordance with the guidelines of the National 
Health and Medical Research Council (Australia). Fresh PCa specimens were obtained with written informed 
consent through the Australian Prostate Cancer BioResource from men undergoing robotic radical prostatec-
tomy at St Andrew’s Hospital (Adelaide, Australia) and cultured for 48 h with 17-AAG, AUY922 (500 nM each) as 
previously described16. Clinicopathological features of tumors used in this study are detailed in Table 1. Tissues 
were cultured at 37 °C for 48 h, then formalin fixed and paraffin-embedded for histology, snap frozen in liquid 
nitrogen for proteomics analysis, or stored in RNAlater for transcriptomic analysis.
www.nature.com/scientificreports/
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RNA Sequencing. Hsp90 inhibitor or vehicle treated patient derived explants (n = 6) preserved in RNAlater 
were homogenized with the Precellys®24 Tissue Homogenizer (Bertin Technologies, France) using 0.5 mL 
Precellys®24 tubes containing 1.4 mm ceramic beads and 500 mL Tri Reagent (Sigma). RNA was then extracted 
using a Qiagen RNeasy mini kit adapted for Tri Reagent using the manufacturer instructions. RNA underwent 
quality control using the Agilent Bioanalyzer (Agilent, Santa Clara, CA) and all samples submitted for sequenc-
ing had an RNA Integrity Number (RIN) ≥6. Library preparation and sequencing were performed at the ACRF 
Cancer Genomics Facility (SA Pathology, Adelaide, Australia). Total RNA samples were treated with Ribo-Zero 
to remove rRNA prior to library construction with the Illumina TruSeq Stranded RNA kit. Sequencing was 
performed on an Illumina HiSeq. 2500 to generate 2 × 125 bp paired-end reads. All samples were pooled and 
run across 3 lanes. Reads were mapped to the human genome (Version hg19) with Tophat2 (Version 2.0.4)58. 
Mapped reads were assembled with CuffLinks (Version 2.2.1)59. Differential expression (DE) analysis was con-
ducted in R using edgeR package (version 3.18.1). After quality control (QC: mean count per million ≥10 for 
at least 3 samples), the initial number of 58,051 genes was reduced to 22,818 genes. Before DE testing, we fitted 
the quasi-likelihood negative binomial generalized log-linear model out after QC data using a robust version of 
edgeR’s glmQLFit function. Next, due to greatly different potency of AUY922 and 17-AAG inhibitors, we used 
two different DE testing strategies. Firstly, AUY922 vs. DMSO and AUY922 vs. 17-AAG comparisons were based 
on edgeR’s glmTreat function with the null absolute fold change set to 1.8, accepting genes with BH adjusted 
P-values less than 5% as DE. Secondly, to detect a much milder effect of the 17-AAG inhibitor, we applied edgeR’s 
glmQLFTest function to the 17-AAG vs. DMSO comparison, accepting genes with BH adjusted P-values less than 
5% and absolute fold change greater than 1.2 as DE. Enrichment barcode plots and heatmaps were generated by 
barcodeplot and heatmap.2 functions from limma and gplots R packages, respectively.
Proteomics Analysis by LC-MS. Snap frozen PDEs (n = 12 patients) were homogenized using the 
Precellys®24 Tissue Homogenizer (Bertin Technologies, France) and 0.5 mL Precellys®24 tubes containing 
1.4 mm ceramic beads and 120 µL ice cold TUC4% buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 30 mM Tris, 
pH 8.5). Tissue lysate was transferred to 1.5 mL Eppendorf tubes and centrifuged at 10,000 rpm for 10 min at 
4 °C before supernatant removed and stored at −80 °C. Frozen tissue lysates were provided to the Adelaide 
Proteomics Centre (University of Adelaide, Adelaide, Australia) where 2D-DIGE proteomics analysis per-
formed as described in60 with the following modifications: Individual explant samples containing 50 μg of protein 
were labelled with Cy3 and Cy5. Separate internal standards were prepared by pooling 25 µg of protein from 
each sample and labelled with Cy2. The dye/protein ratio for all samples was 200 pmol/50 μg. Pharmalyte 3–10 
(GE Healthcare) was added to all samples prior to isoelectric focusing, which was performed on 24 cm 3–10 
non-linear (NL) immobilized pH gradient (IPG) strips (Biorad). Proteins were focused for 27,000 Volt-hours at 
8,000 V. SDS-PAGE in the second dimension was carried out using 12.5% 2DGel DALT NF pre-cast polyacryla-
mide gels (Gel Company). Gels were scanned using an Ettan DIGE Imager (GE Healthcare) at 100 μm resolution 
and analysis undertaken using DeCyder 2D software (version 7, GE Healthcare). In Difference In-gel Analysis 
(DIA) mode, spot detection was performed based on an estimated 5,000 spots. Exclusion filters were set to reject 
spots with a slope of >2, an area of <400, a volume of <30,000 and a peak height of <300 and >100,000. Each gel 
image was processed separately in the Differential In-gel Analysis (DIA) module of DeCyder for spot detection 
prior to export to the Biological Variation Analysis (BVA) module. Protein abundance in AUY922 treated PDEs 
Analysis Patient ID
Age at RP 
(years)
PSA at RP 
(ng/mL) Gleason Grade Pathologic Stage
transcriptomics 1921 52 6.3 4 + 3 = 7 PT3A
transcriptomics 1963 59 12 5 + 5 = 10 PT3A
transcriptomics 1967 70 13 4 + 3 = 7 PT3B
transcriptomics 1970 56 2.4 3 + 4 = 7 PT2C
transcriptomics 2100 63 19.6 4 + 3 = 7 PT3B
transcriptomics 2117 51 8 3 + 4 = 7 PT3A
proteomics 1381 60 7.7 4 + 3 = 7 PT3B
proteomics 1411 58 5.7 3 + 4 = 7 PT2C
proteomics 1420 62 5.1 3 + 4 = 7 PT3A
proteomics 1424 66 9.1 3 + 3 = 6 PT3A
proteomics 1439 63 6.8 3 + 3 = 6 PT2C
proteomics 1455 61 5.2 5 + 4 = 9 PT3B
proteomics 1463 67 15 4 + 3 = 7 PT2C
proteomics 1490 66 6.4 4 + 3 = 7 PT3B
proteomics 1581 63 17 4 + 3 = 7 PT3A
proteomics 1596 66 6.6 4 + 5 = 9 PT3A
proteomics 1622 72 13 3 + 4 = 7 PT2C
proteomics 1628 74 7.1 3 + 4 = 7 PT2C
Table 1. Pathologic characteristics of tumors used in this study. All tumors are adenocarcinoma of acinar type 
and pathologic stages are as per AJCC TNM 7th Edition.
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was subjected to statistical comparison with its vehicle and 17-AAG treated counterpart to detect spots that are 
differentially expressed using paired two-tailed Student’s t-test. Spots that returned a p-value of <0.05 were con-
sidered differentially expressed.
Extraction of protein from cell lines. PCa cells were seeded in 6-well culture plates [1.5 × 105 cells per 
well] and cultured for 24 h prior to treatment as indicated. Protein lysates were collected from LNCaP and PC-3 
cells following 48 h treatment with vehicle or the indicated doses of AUY922 or 17-AAG. Cells were washed 
in PBS and lysed directly from 6-well plates using RIPA buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% 
TX-100) containing protease inhibitor cocktail (Sigma-Aldrich). Cells were scraped and collected into a 1.5 mL 
Eppendorf tube and homogenized with a 26 G needle prior to centrifugation at 10,000 rpm for 10 mins at 4 °C. 
Supernatant was collected and stored at −80 °C.
Western Blotting. Whole cell protein lysates were prepared as described above and analyzed by Western 
blot as described previously61. Proteins were digitally imaged using the ChemiDoc™ XRS (BioRad). Full length 
blots can be found in Supplementary Figure 6.
Cell Motility. LNCaP and PC-3 PCa cells grown in RPMI with 10% or 5% FBS respectively, were seeded in 
24-well Image Lock plates (Essen BioScience) at a density of 4 × 104 cells per well, and cultured for 24 h prior to 
treatment. The seeding media was then replaced with growth media containing either vehicle (DMSO), 17-AAG 
or AUY922 at doses equivalent to IC50 (25 nM AUY922, 50 nM 17-AAG) or 2x IC50 (50 nM AUY922, 100 nM 
17-AAG). Cells were placed in an IncuCyte (Essen BioScience) live cell analysis system, and images of the cells 
were captured using 20x magnification at 10 min intervals for 48 h. The image sets from each treatment were 
imported into ImageJ v1.49t, where the plugin MTrackJ was used to track the movement of individual cells over 
time. Tracking of a cell would cease if the cell a) divided b) died c) lifted from the plate or d) moved out of view. 
Cell motility was calculated as cell track length (pixels) per minute.
Immunofluorescence. Cells were seeded in 6-well plates [1 × 105 cells per well] onto circle glass cover slips 
of 0.6 µm thickness (Thermo Fisher) and allowed to attach for 24 h. Cells were treated for 48 h with AUY922 
(25 nM), then fixed in 4% paraformaldehyde for 20 min and permeabilized using 0.1% TritonX-100 for 10 min. 
Cells were incubated in blocking buffer (10% serum in PBS) for 30 min at room temperature before immunos-
taining with primary antibody for 2 h at room temperature followed by appropriate fluorophore-conjugated sec-
ondary antibody (anti-goat Cy3, anti-mouse Alexa Fluor 594, anti-rabbit Alexa Fluor 488; 1:250) for 1 h at room 
temperature in the dark. Cover slips were mounted using Prolong Gold™ Antifade Mountant Media containing 
DAPI and cured for 48 h before imaging on a Leica SP8 confocal microscope.
The cellular tubulin polymer mass was measured based on the mean α-tubulin fluorescence intensity as 
described in62. Optical 96-well plates (ibidi) were coated with poly-L-ornithine (Sigma-Aldrich), and LNCaP cells 
[5 × 103 cells per well] were seeded and allowed to attach for 24 h. Cells were treated for 48 h with the indicated 
doses of inhibitors (3 wells/treatment) after which cells were fixed with ice-cold methanol for 3 min, incubated 
in blocking buffer [2% bovine serum albumin (Sigma-Aldrich) in TBS with 0.1% Triton X-100] for 30 min at 
room temperature before immunostaining for 1 h at room temperature with primary antibody against α-tubulin 
(DM1A, ab7291, Abcam, 1:500). Cells were washed twice in TBS-T and incubated with the appropriate second-
ary, fluorophore-labelled antibody for 1 h at room temperature in the dark. DNA was counterstained with 1 µg/
mL DAPI [4′,6-diamidino-2-phenylindole; Sigma-Aldrich]. Methanol fixation and permeabilization with Triton 
X-100 were performed to wash out soluble tubulin subunits63,64. Cells were imaged on an INCell 2200 automated 
imaging systems (GE Healthcare) at 20x magnification. Image segmentation of ~4,500 cells/treatment and quan-
titation of mean α-tubulin fluorescence intensity were performed with CellProfiler software (Broad Institute, 
Cambridge, USA)65. All data points were performed in technical triplicates and are reported as the mean ± SD.
Cellular Fractionation. Cells were seeded in 6-well plates [1.0 × 105 cells per well] and allowed to attach 
for 24 h. Cells were treated for 48 h with the indicated dose of inhibitor, then trypsinized and an equal number 
of cells collected from each sample for fractionation. Cells were resuspended in 300 μL of lysis buffer 1 (50 mM 
Hepes-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% TX-100) containing protease 
inhibitor cocktail (Sigma-Aldrich), and 100 μL of suspension was collected as whole lysate. Samples were centri-
fuged at 9,300 rcf for 10 sec and 100 μL supernatant collected as cytoplasmic lysate. Remaining cells were washed 
in lysis buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) containing protease inhib-
itor cocktail (Sigma-Aldrich), and resuspended in 100 μL lysis buffer 3 (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 
1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine) containing protease inhibitor 
cocktail (Sigma-Aldrich). All samples were sonicated at high intensity for 10 × 30 sec with a 1 min rest on ice 
followed by centrifugation at 15,700 rcf for 10 min.
Enzyme-linked immunosorbent assay (ELISA). LNCaP cells were seeded in 6-well culture plates 
[1.5 × 105 cells per well] and allowed to adhere for 24 h. Cells were treated for 48 h in FN-1 free HPC1 media 
(Sigma-Aldrich) with vehicle or AUY922 (25 nM). Culture medium was collected from the cells and gently cen-
trifuged to generate cell-free media, which was immediately snap frozen. ELISA plates (Jomar Bioscience cat# 
BMS2028) were assayed according to the manufacturer’s instructions. Cells remaining in the plate were trypsin-
ized and total cell number for each sample was determined to calculate the amount of protein secretion per cell.
In vitro tubulin polymerization assay. Microtubule assembly was studied using the CytoDYNAMIX 
Screen kit (BK006P; Cytoskeleton Inc., Denver, CO, USA). Purified porcine tubulin protein (>99% purity) was 
resuspended in G-PEM buffer containing 80 mM PIPES, 2 mM MgCl2, 0.5 mM EGTA, 1 mM GTP (pH 6.9) and 
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15% glycerol in the absence or presence of indicated compounds at 4 °C. The mixture was transferred into a 
pre-warmed 96-well plates, and polymerization was monitored (absorbance) using a FLUOstar Omega plate 
reader (BMG LABTECH) at 340 nm every 1 min for 60 min at 37 °C.
Exosome preparation and NanoSight particle tracking analysis. Cells (LNCaP, PC-3 and 22Rv1) 
seeded at 60–80% confluency were cultured with DMSO control, 25 nM or 50 nM AUY922 in exosome-depleted 
media for 48 h. Medium was collected and exosomes were isolated as described previously22. The concentration 
of exosomes released was quantified using Nanoparticle Tracking Analysis (NTA) software version 2.3 on the 
NanoSight LM10-HS10 system (NanoSight Amesbury, UK). When quantifying exosomes released, samples were 
diluted in exosome-free pre-filtered PBS to obtain measurable concentrations between 0.5 × 108 and 5 × 109 par-
ticles/mL. For each sample dilution, three “real-time” readings were taken, and the data presented is the average 
+/−SEM of these 3 readings.
Transwell invasion assay. 3D invasion assays were conducted using 24-well Falcon BioCoat Matrigel 
invasion chambers (#FAL354480, In Vitro Technologies, VIC, Australia). PC-3 cells (5 × 105) were transfected 
using 5 µM RNAiMax according to the manufacturer’s instructions with 5 pmol siRNA against FN1 (Dharmacon 
J-009853-07, J-009853-06), or non-targeting siRNA (Dharmacon D-001810-01) as a negative control for 48 h 
before harvesting for the invasion assay. In order to evaluate the effect of AUY922 and pUR4 on cell invasion, 
PC-3 cells (3 × 105) were seeded in 6-well plates and allowed to adhere overnight. Cells then were treated with 
either AUY922 (25 and 50 nM), or pUR4 (500 nM) for 48 h before harvesting for the invasion assay. DMSO (0.5%) 
or the control peptide III-11C (500 nM) were used as negative controls. Treated or siRNA-transfected cells were 
seeded into the upper chamber of the Transwell at a density of 1 × 105 cells/well in serum-free medium. The 
bottom chamber was filled with 650 µL of RPMI-1640 medium containing 5% FBS. The inserts were incubated at 
37 °C for 48 h. Non-migrated cells were removed from the upper surface of the membrane with a cotton swab, and 
the membranes were washed three times with PBS. Migrated cells remaining on the bottom surface were fixed 
in formalin for 20 min, washed and stained with crystal violet for 30 min. Five random fields for each membrane 
were photographed using the Axio Scope A1 Fluorescent Microscope (Zeiss), and the number of migrated cells 
was counted manually and presented as percent of control cells ± SEM.
Statistical Analysis. One-way ANOVA with Dunnet’s multiple comparisons test (GraphPad Prism 7 
software, GraphPad Software) was used for statistical analysis in this study (ns = non-significant, *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001).
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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